Inovio Pharmaceuticals (INO) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Inovio Pharmaceuticals is expected to announce its Q2 2025 earnings on August 12, with analysts predicting a loss of ($0.65) per share and revenue of $0.01 million.
• Shares traded at $1.50 with a market cap of $54.83 million, while the stock has fluctuated between a 52-week low of $1.30 and a high of $9.10.
• Analysts have mixed ratings on INO, with a consensus rating of "Moderate Buy" and an average target price of $8.80 amidst recent updates on price targets from various firms.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $0.01 million for the quarter.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.23. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.01 million. On average, analysts expect Inovio Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ:INO traded up $0.03 during midday trading on Tuesday, reaching $1.50. 638,184 shares of the company's stock were exchanged, compared to its average volume of 1,129,769. The firm's 50 day simple moving average is $1.77 and its two-hundred day simple moving average is $1.87. Inovio Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $9.10. The stock has a market cap of $54.83 million, a price-to-earnings ratio of -0.47 and a beta of 1.38.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on INO shares. Oppenheimer lowered their target price on Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating for the company in a report on Wednesday, May 14th. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $5.00 price objective on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 14th. Wall Street Zen raised Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday, June 27th. Finally, Piper Sandler started coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, July 9th. They set an "overweight" rating and a $5.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $8.80.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Inovio Pharmaceuticals stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) by 39.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 20,781 shares of the biopharmaceutical company's stock after purchasing an additional 5,894 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.06% of Inovio Pharmaceuticals worth $34,000 at the end of the most recent reporting period. 26.79% of the stock is currently owned by institutional investors and hedge funds.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.